Skip to main content
Top
Published in: European Journal of Pediatrics 7/2022

Open Access 06-05-2022 | Spinal Muscular Atrophy | Original Article

Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening

Authors: Marika Pane, Maria Alice Donati, Costanza Cutrona, Roberto De Sanctis, Matteo Pirinu, Giorgia Coratti, Martina Ricci, Concetta Palermo, Beatrice Berti, Daniela Leone, Chiara Ticci, Michele Sacchini, Margherita Cerboneschi, Anna Capasso, Gianpaolo Cicala, Maria Carmela Pera, Chiara Bravetti, Emanuela Abiusi, Alessandro Vaisfeld, Giovanni Vento, Francesco Danilo Tiziano, Eugenio Mercuri

Published in: European Journal of Pediatrics | Issue 7/2022

Login to get access

Abstract

The possibility to identify patients with spinal muscular atrophy through neonatal screenings has highlighted the need for clinical assessments that may systematically evaluate the possible presence of early neurological signs. The aim of this study was to use the Hammersmith Neonatal Neurological Examination (HNNE) and a module specifically designed for floppy infants to assess the possible variability of neurological findings in infants identified through neonatal screening. The infants included in this study were identified as part of a pilot study exploring neonatal screening in two Italian regions. A neurological examination was performed using the HNNE and an additional module developed for the assessment of floppy infants. Seventeen infants were identified through the screening. One patient had 1 SMN2 copy, 9 had 2 copies, 3 had 3, and 4 had more than 3 copies. Nine of the 17 infants (53%) had completely normal results on both scales, 3 had minimal signs, and the other 5 had more obvious clinical signs. The number of SMN2 copies was related to the presence of abnormal neurological signs (p = 0.036) but two SMN2 copies were associated with variable clinical signs as they were found in some infants with respectively normal examination or obvious severe early signs.
Conclusions: Our results suggest that the combination of both scales increases the possibility to detect neonatal neurological signs and to define different early patterns of involvement also identifying paucisymptomatic patients.
What is Known:
• The use of new therapeutic options in presymptomatic SMA patients leads to a dramatic reduction of the onset and severity of the diesease.
• The already existing tools commonly used in Type I SMA (HINE and CHOP-intend) may not be suitable to identify minor neurological signs in the neonatal period.
What is New:
• Combining the HNNE and the floppy infant module, we were able to identify early neurological signs in SMA infants identified through newborn screening and may help to predict the individual therapeutic outcome of these patients.
• Iinfants with 2 SMN2 copies identified through the screening had a more variable neonatal examination compared to those with three or more copies, in agreement with similar findings in older infants.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F (2020) Spinal muscular atrophy - insights and challenges in the treatment era. Nat Rev Neurol 16:706–715CrossRef Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F (2020) Spinal muscular atrophy - insights and challenges in the treatment era. Nat Rev Neurol 16:706–715CrossRef
2.
go back to reference Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713–1722CrossRef Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713–1722CrossRef
3.
go back to reference Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, Group ES (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723–1732CrossRef Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, Group ES (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723–1732CrossRef
4.
go back to reference Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS, Group CS (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625–635CrossRef Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS, Group CS (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625–635CrossRef
5.
go back to reference Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, Mercuri E, Rose K, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Seabrook T, Fontoura P, Servais L, Group FW (2021) Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med 384:915–923CrossRef Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, Mercuri E, Rose K, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Seabrook T, Fontoura P, Servais L, Group FW (2021) Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med 384:915–923CrossRef
6.
go back to reference Darras BT, Masson R, Mazurkiewicz-Beldzinska M, Rose K, Xiong H, Zanoteli E, Baranello G, Bruno C, Vlodavets D, Wang Y, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Fontoura P, Servais L, Group FW (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385:427–435CrossRef Darras BT, Masson R, Mazurkiewicz-Beldzinska M, Rose K, Xiong H, Zanoteli E, Baranello G, Bruno C, Vlodavets D, Wang Y, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Fontoura P, Servais L, Group FW (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385:427–435CrossRef
7.
go back to reference De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, Kirschner J et al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 29:842–856CrossRef De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, Kirschner J et al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 29:842–856CrossRef
8.
go back to reference Boemer F, Caberg JH, Dideberg V, Dardenne D, Bours V, Hiligsmann M, Dangouloff T, Servais L (2019) Newborn screening for SMA in Southern Belgium. Neuromuscul Disord 29:343–349CrossRef Boemer F, Caberg JH, Dideberg V, Dardenne D, Bours V, Hiligsmann M, Dangouloff T, Servais L (2019) Newborn screening for SMA in Southern Belgium. Neuromuscul Disord 29:343–349CrossRef
9.
go back to reference Kraszewski JN, Kay DM, Stevens CF, Koval C, Haser B, Ortiz V, Albertorio A, Cohen LL, Jain R, Andrew SP, Young SD, LaMarca NM, De Vivo DC, Caggana M, Chung WK (2018) Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med 20:608–613CrossRef Kraszewski JN, Kay DM, Stevens CF, Koval C, Haser B, Ortiz V, Albertorio A, Cohen LL, Jain R, Andrew SP, Young SD, LaMarca NM, De Vivo DC, Caggana M, Chung WK (2018) Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med 20:608–613CrossRef
10.
go back to reference Vill K, Schwartz O, Blaschek A, Glaser D, Nennstiel U, Wirth B, Burggraf S, Roschinger W, Becker M, Czibere L, Durner J, Eggermann K, Olgemoller B, Harms E, Schara U, Kolbel H, Muller-Felber W (2021) Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet J Rare Dis 16:153CrossRef Vill K, Schwartz O, Blaschek A, Glaser D, Nennstiel U, Wirth B, Burggraf S, Roschinger W, Becker M, Czibere L, Durner J, Eggermann K, Olgemoller B, Harms E, Schara U, Kolbel H, Muller-Felber W (2021) Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet J Rare Dis 16:153CrossRef
11.
go back to reference Kariyawasam DST, Russell JS, Wiley V, Alexander IE, Farrar MA (2020) The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med 22:557–565CrossRef Kariyawasam DST, Russell JS, Wiley V, Alexander IE, Farrar MA (2020) The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med 22:557–565CrossRef
12.
go back to reference Kay DM, Stevens CF, Parker A, Saavedra-Matiz CA, Sack V, Chung WK, Chiriboga CA, Engelstad K, Laureta E, Farooq O, Ciafaloni E, Lee BH, Malek S, Treidler S, Anziska Y, Delfiner L, Sakonju A, Caggana M (2020) Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet Med 22:1296–1302CrossRef Kay DM, Stevens CF, Parker A, Saavedra-Matiz CA, Sack V, Chung WK, Chiriboga CA, Engelstad K, Laureta E, Farooq O, Ciafaloni E, Lee BH, Malek S, Treidler S, Anziska Y, Delfiner L, Sakonju A, Caggana M (2020) Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet Med 22:1296–1302CrossRef
13.
go back to reference Haataja L, Cowan F, Mercuri E, Bassi L, Guzzetta A, Dubowitz L (2003) Application of a scorable neurologic examination in healthy term infants aged 3 to 8 months. J Pediatr 143:546CrossRef Haataja L, Cowan F, Mercuri E, Bassi L, Guzzetta A, Dubowitz L (2003) Application of a scorable neurologic examination in healthy term infants aged 3 to 8 months. J Pediatr 143:546CrossRef
14.
go back to reference Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, Scott C, Pane M, Messina S, Bertini E, Mercuri E, Finkel RS (2010) The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 20:155–161CrossRef Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, Scott C, Pane M, Messina S, Bertini E, Mercuri E, Finkel RS (2010) The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 20:155–161CrossRef
15.
go back to reference Dubowitz L, Mercuri E, Dubowitz V (1998) An optimality score for the neurologic examination of the term newborn. J Pediatr 133:406–416CrossRef Dubowitz L, Mercuri E, Dubowitz V (1998) An optimality score for the neurologic examination of the term newborn. J Pediatr 133:406–416CrossRef
17.
go back to reference Dubowitz V (1999) Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 3:49–51CrossRef Dubowitz V (1999) Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 3:49–51CrossRef
18.
go back to reference De Sanctis R, Pane M, Coratti G, Palermo C, Leone D, Pera MC, Abiusi E, Fiori S, Forcina N, Fanelli L, Lucibello S, Mazzone ES, Tiziano FD (2018) Mercuri E (2017) Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. Neuromuscul Disord 28(1):24–28CrossRef De Sanctis R, Pane M, Coratti G, Palermo C, Leone D, Pera MC, Abiusi E, Fiori S, Forcina N, Fanelli L, Lucibello S, Mazzone ES, Tiziano FD (2018) Mercuri E (2017) Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. Neuromuscul Disord 28(1):24–28CrossRef
19.
go back to reference Pane M, Lapenta L, Abiusi E, de Sanctis R, Luigetti M, Palermo C, Ranalli D, Fiori S, Tiziano FD, Mercuri E (2017) Longitudinal assessments in discordant twins with SMA. Neuromuscul Disord 27:890–893CrossRef Pane M, Lapenta L, Abiusi E, de Sanctis R, Luigetti M, Palermo C, Ranalli D, Fiori S, Tiziano FD, Mercuri E (2017) Longitudinal assessments in discordant twins with SMA. Neuromuscul Disord 27:890–893CrossRef
20.
go back to reference Calucho M, Bernal S, Alias L, March F, Vencesla A, Rodriguez-Alvarez FJ, Aller E, Fernandez RM, Borrego S, Millan JM, Hernandez-Chico C, Cusco I, Fuentes-Prior P, Tizzano EF (2018) Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28:208–215CrossRef Calucho M, Bernal S, Alias L, March F, Vencesla A, Rodriguez-Alvarez FJ, Aller E, Fernandez RM, Borrego S, Millan JM, Hernandez-Chico C, Cusco I, Fuentes-Prior P, Tizzano EF (2018) Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28:208–215CrossRef
21.
go back to reference Finkel R, Bertini E, Muntoni F, Mercuri E, Group ESWS (2015) 209th ENMC International workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7–9 November 2014, Heemskerk, The Netherlands. Neuromuscul Disord 25:593–602CrossRef Finkel R, Bertini E, Muntoni F, Mercuri E, Group ESWS (2015) 209th ENMC International workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7–9 November 2014, Heemskerk, The Netherlands. Neuromuscul Disord 25:593–602CrossRef
Metadata
Title
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening
Authors
Marika Pane
Maria Alice Donati
Costanza Cutrona
Roberto De Sanctis
Matteo Pirinu
Giorgia Coratti
Martina Ricci
Concetta Palermo
Beatrice Berti
Daniela Leone
Chiara Ticci
Michele Sacchini
Margherita Cerboneschi
Anna Capasso
Gianpaolo Cicala
Maria Carmela Pera
Chiara Bravetti
Emanuela Abiusi
Alessandro Vaisfeld
Giovanni Vento
Francesco Danilo Tiziano
Eugenio Mercuri
Publication date
06-05-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics / Issue 7/2022
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-022-04470-3

Other articles of this Issue 7/2022

European Journal of Pediatrics 7/2022 Go to the issue